Today I am excited to introduce the Truveta Platform for health systems and life science companies, share new insights about COVID-19 from the Truveta Platform, and welcome three new large regional health systems – Ochsner Health, Saint Luke’s Health System and UnityPoint Health – as members.
One of the greatest travesties of COVID-19 has been the failure of public institutions in the U.S. to combat the pandemic using real-time data. The U.S. is one of the few developed countries to lack a national COVID-19 dashboard with rich insights for effectively managing the pandemic. Most of the decisions made for COVID-19 have relied on outdated data from other countries not reflective of the diversity of the U.S. The death and hospitalization rates in our country reflect this failure. With the moral imperative to address this significant gap, Truveta was born from innovative health systems who came together to deliver an unprecedented national dataset for U.S. health – to advance care for patients with COVID-19 or any other condition.
Truveta now represents more than 16% of U.S. clinical care from tens of thousands of sites of care across 42 states, representing the full diversity of the country across age, geography, race, ethnicity, and gender. With each new health system that joins Truveta, our customers can research rarer and more precision conditions accelerating the insights needed for better patient care. We’ve also now secured nearly $200 million in funding to accelerate the development of this unprecedented data platform.
Today, we are sharing the first COVID-19 insights in the U.S. using real-time data from the Truveta Platform, representing a major step forward in realizing our vision of saving lives with data.
The first COVID-19 insights for the US using Real-world Data
As we share these first insights from the Truveta Platform, I am struck by the speed at which our 20 health system members and Truveta have come together to normalize and de-identify health data in record time for the most current picture of our nation’s health. We chose to focus on COVID-19 as our first area of research as the world continues to wage the battle against this pandemic.
The COVID-19 insights from the Truveta Platform shared today provide a glimpse of the knowledge awaiting researchers. This real-world, comprehensive data has led to new COVID-19 insights, including:
- Adverse events occur in less than 1% of people fully vaccinated. Moderna vaccinated patients are showing 40% more adverse events than Pfizer.*
- 9% to 15% of people who have a breakthrough infection of COVID-19 end up hospitalized, with Pfizer and Moderna vaccinated patients showing the 9% trend and Johnson & Johnson patients at 15%.*
- 1 in 4 people with chronic kidney disease who have a breakthrough infection end up in the hospital. Of all high-risk conditions studied, patients with chronic kidney disease required hospitalization the most.**
- People with high-risk conditions, like cancer, HIV or organ transplants, are no more likely than the general population to have a breakthrough case, which likely reflects their risk averse behaviors. When they do get infected, they end up hospitalized twice as often.**
What has taken some scientific teams many months to do, our team was able to conceive and deliver a COVID-19 study using one of the largest datasets to date in less than two weeks with clinical accuracy. Our first clinical study from the Truveta Clinical Research team highlights new insights on the association between COVID-19 breakthrough infections and hospitalizations in people with high-risk conditions.
The Truveta Platform Delivers Real-time Insights for Health
These insights were made possible by the Truveta Platform, which enables researchers to find cures faster, empower every clinician to be an expert, and help families make the most informed decisions about their care. Data in the Truveta Platform is de-identified, updated daily, and comprehensive, including all EHR data such as labs, vitals, diagnosis codes, procedure codes, physician notes, and pathology reports. This data scale enables researchers to gather new insights and delivers generalizable results with statistical power. Data is refreshed daily and continuously flowing, providing researchers with an unprecedented opportunity to learn about our nation’s health every day.
We normalize data for faster insights using AI and machine learning and carefully de-identify data compliant with HIPAA, while retaining patient journey timelines. Once de-identified, aggregate data flows into the Truveta Platform where researchers have many options to analyze the data, including exporting into their preferred analysis tools, the Truveta application, within Jupyter notebooks, with APIs, or viewing in customizable daily dashboards.
Our custom COVID-19 dashboards, for example, give early adopter customers views on vaccinated and unvaccinated populations, breakthrough cases, vaccine effectiveness, and outcomes like hospitalized or not. The dashboard is interactive, allowing researchers to select populations to study by age, sex, race, comorbidity and vaccine dose and company. The dashboard also includes reporting on frequency of adverse events and adverse events over time by vaccine dose and company.
For life science companies, the Truveta Platform offers unprecedented access to real-world data on how any drug or device is currently being used every day across the U.S., enabling researchers to find cures faster. Researchers can use the Truveta Platform to monitor safety and comparative effectiveness of drugs and therapeutics, inform label expansion efforts to serve more patients, explore patient journeys to inform research and development, and identify clinical trial sites for equitable trials.
For health systems, Truveta is an opportunity for innovative health systems to join together and apply their collective de-identified data to improve patient care, advance health equity, and expedite understanding of rare diseases. For health system members, we create a custom Truveta Embassy – a secure, private cloud-based container– to normalize their data for use in their operations and research. Using insights from their Truveta Embassy or the aggregate de-identified data in the Truveta Platform, physicians and researchers can rapidly learn and advance care by comparing insights from their own system with the national dataset.
The global pandemic created a moral imperative to build Truveta and we’ve done it at record speed hand in hand with our health system members. We’re humbled to share these first COVID-19 insights. Our early insights from real-world data give just a glimpse of what we can learn with the Truveta Platform. We invite early adopter medical researchers and life science companies to join us to explore the data and create custom research.
Today represents a major step forward in realizing our vision of saving lives with data and we can’t wait to enable your ethical research with the Truveta Platform.
Insights generated from the Truveta Platform are real-time and updated daily as data from more health systems is de-identified and integrated into the Truveta Platform, revealing up-to-date insights as the nation’s health evolves.
* Data for these COVID-19 insights included more than 13 million clinical records.
**For full analysis of Truveta’s study, including statistical approaches and data sources, read more details here.